<?xml version="1.0" encoding="UTF-8"?>
<p>Early reports of ebolavirus studies in HIS mice were based on work in NOD/SCID 
 <italic>Il2rɣ
  <sub>c</sub>
 </italic>
 <sup>−/−</sup> mice engrafted with human PBL (NSG-huPBL) using both mouse-adapted and wild-type EBOV [
 <xref rid="B36-vaccines-08-00098" ref-type="bibr">36</xref>]. Similar to infection in non-HIS mice, wild-type EBOV infection did not result in lethal disease in NSG-huPBL. Later, studies were performed using more advanced HIS models [
 <xref rid="B56-vaccines-08-00098" ref-type="bibr">56</xref>,
 <xref rid="B57-vaccines-08-00098" ref-type="bibr">57</xref>]. The human cell-engrafted NOD.Cg-
 <italic>Prkdc
  <sup>scid</sup> Il2rg
  <sup>tm1Wjl</sup>
 </italic> Tg (HLA-A2.1) 1Enge/Sz mice (hu-NSG-A2) that express human HLA-A2 provided the first platform for a lethal EBOV mouse model without the need of prior virus adaption to the host [
 <xref rid="B38-vaccines-08-00098" ref-type="bibr">38</xref>]. Lethal disease is observed in hu-NSG-A2 following intraperitoneal [
 <xref rid="B58-vaccines-08-00098" ref-type="bibr">58</xref>] or intranasal inoculation with the prototypic EBOV Mayinga strain [
 <xref rid="B37-vaccines-08-00098" ref-type="bibr">37</xref>]. 
</p>
